Alina M. Allen

Transplant Surgery

200 1st St SW
Rochester, MN 55905

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 133 publications

Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Extrahepatic Cancers and Sarcopenia.

Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Extrahepatic Cancers and Sarcopenia.

Journal: Clinics in liver disease

Published: May 16, 2026

Sequential FIB-4-based testing limits detection of fibrotic MASLD despite optimized ELF thresholds.

Sequential FIB-4-based testing limits detection of fibrotic MASLD despite optimized ELF thresholds.

Journal: Hepatology communications

Published: March 05, 2026

Author Correction: Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial.

Author Correction: Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial.

Journal: Nature medicine

Published: February 10, 2026

Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography.

Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography.

Journal: Hepatology communications

Published: February 10, 2026

Diagnostic Deserts: National Gaps in Screening and Care Infrastructure for Metabolic Dysfunction-Associated Steatotic Liver Disease.

Diagnostic Deserts: National Gaps in Screening and Care Infrastructure for Metabolic Dysfunction-Associated Steatotic Liver Disease.

Journal: The American journal of gastroenterology

Published: February 05, 2026

Clinician engagement shapes the impact of AI-based ECG screening for chronic liver disease in primary care.

Clinician engagement shapes the impact of AI-based ECG screening for chronic liver disease in primary care.

Journal: NPJ digital medicine

Published: February 03, 2026

Optimized MASH treatment eligibility cutoffs for MRE-measured liver stiffness and proton density fat fraction.

Optimized MASH treatment eligibility cutoffs for MRE-measured liver stiffness and proton density fat fraction.

Journal: Clinical and molecular hepatology

Published: November 10, 2025

Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes.

Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes.

Journal: JAMA network open

Published: November 06, 2025

Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.

Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.

Journal: Hepatology (Baltimore, Md.)

Published: October 31, 2025

Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. cities.

Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. cities.

Journal: Annals of hepatology

Published: October 23, 2025

Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Journal: Gastroenterology

Published: September 18, 2025

Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Journal: Gastroenterology

Published: September 18, 2025

Showing 1-12 of 133

Last Updated: 09/26/2026